Overview
Harry Drabkin is an Oncologist and a Hematologist in Denver, Colorado. Dr. Drabkin is rated as an Advanced provider by MediFind in the treatment of Familial Wilms Tumor 2. His top areas of expertise are Renal Cell Carcinoma (RCC), Adult Soft Tissue Sarcoma, Chromophobe Renal Cell Carcinoma, and WT1-Related Wilms Tumor Syndromes. Dr. Drabkin is currently accepting new patients.
His clinical research consists of co-authoring 25 peer reviewed articles and participating in 1 clinical trial. MediFind looks at clinical research from the past 15 years.
Insurance
Accepted insurance can change. Please verify directly with the provider.
Accepted insurance plans:
- HMO
- INDEMNITY
- POS
- PPO
- EPO
- HMO
- POS
- PPO
- EPO
- HMO
- INSURANCE PLAN
- MANAGED MEDICAID PLAN
- MEDICARE MAPD
- MEDICARE PDP
- MEDICARE SNP
- MEDICARE-MEDICAID PLAN
- OTHER MEDICARE
- OTHER MEDICARE PART D
Locations
2555 S Downing St 1st Floor, Whcc Wh Cherry Creek, Denver, CO 80210
Clinical Research
Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.
1 Clinical Trials
Poudre Valley Medical Group LLC
James Moore is an Oncologist and a Hematologist in Fort Collins, Colorado. Dr. Moore is rated as a Distinguished provider by MediFind in the treatment of Familial Wilms Tumor 2. His top areas of expertise are Mantle Cell Lymphoma (MCL), Chromophobe Renal Cell Carcinoma, Familial Wilms Tumor 2, and WT1-Related Wilms Tumor Syndromes. Dr. Moore is currently accepting new patients.
University Physicians Incorporated
Elaine Lam is a Hematologist Oncology specialist and an Oncologist in Aurora, Colorado. Dr. Lam is rated as a Distinguished provider by MediFind in the treatment of Familial Wilms Tumor 2. Her top areas of expertise are Clear Cell Sarcoma, Chromophobe Renal Cell Carcinoma, WT1-Related Wilms Tumor Syndromes, and Renal Cell Carcinoma (RCC). Dr. Lam is currently accepting new patients.
Portercare Adventist Health System
Jose Pacheco is an Oncologist and a Hematologist in Littleton, Colorado. Dr. Pacheco is rated as a Distinguished provider by MediFind in the treatment of Familial Wilms Tumor 2. His top areas of expertise are Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Small Cell Lung Cancer (SCLC), and EGFR Positive Lung Cancer.
Areas of Expertise
MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.
Learn more about MediFind’s expert tiers
- Distinguished
- Adult Soft Tissue SarcomaDr. Drabkin isDistinguished. Learn about Adult Soft Tissue Sarcoma.
- Chromophobe Renal Cell CarcinomaDr. Drabkin isDistinguished. Learn about Chromophobe Renal Cell Carcinoma.
- Renal Cell Carcinoma (RCC)Dr. Drabkin isDistinguished. Learn about Renal Cell Carcinoma (RCC).
- WT1-Related Wilms Tumor SyndromesDr. Drabkin isDistinguished. Learn about WT1-Related Wilms Tumor Syndromes.
- Advanced
- Clear Cell SarcomaDr. Drabkin isAdvanced. Learn about Clear Cell Sarcoma.
- Familial Wilms Tumor 2Dr. Drabkin isAdvanced. Learn about Familial Wilms Tumor 2.
- Wilms TumorDr. Drabkin isAdvanced. Learn about Wilms Tumor.
- Experienced
- Bladder CancerDr. Drabkin isExperienced. Learn about Bladder Cancer.
- Lung CancerDr. Drabkin isExperienced. Learn about Lung Cancer.
- Muscle Invasive Bladder CancerDr. Drabkin isExperienced. Learn about Muscle Invasive Bladder Cancer.
- Non-Muscle Invasive Bladder CancerDr. Drabkin isExperienced. Learn about Non-Muscle Invasive Bladder Cancer.
- Non-Small Cell Lung Cancer (NSCLC)Dr. Drabkin isExperienced. Learn about Non-Small Cell Lung Cancer (NSCLC).
- Urothelial CancerDr. Drabkin isExperienced. Learn about Urothelial Cancer.